Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Nexstim announces agreement on growth financing

By Antti SiltanenAnalyst
Nexstim

Translation: Original comment published in Finnish on 8/11/2023 at 6:30 am EEST.

Nexstim announced on Thursday that it has agreed a EUR 1.5 million loan with Nordea. According to the press release, the loan will finance strategic investments, growth and working capital needs. The term of the loan is five years and the loan is expected to be drawn down during August. We estimate that the loan could be linked to Nexstim's clinic network investments, but in the absence of further information, we are waiting for more details for now.

Nexstim has been preparing for a long time to expand its network of clinics

In January 2022, Nexstim announced a strategic investment in a Californian clinic services company. PNC Management Services, LLC provides management, consulting, administrative and other support services to the local TMS clinic. In March 2022, the company announced the establishment of an investment company, which we understand will be tasked with making investments in similar types of clinic service companies. We estimate that the investments may also involve equipment sales. Expansion of the clinic network has been a strategic focus area for Nexstim since last year, but no new investments have been heard of since PNC Management Services. We estimate that the funding now agreed could be linked to the expansion of the clinic network, either in Europe or the US. At this stage, however, no further details on the use of the funding are available, so we await further information on the subject.

Login required

This content is only available for logged in users

Create account

Nexstim operates in medical technology. The company has developed a non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation (nTMS) technology with 3D navigation providing targeting of the TMS to the specific area of the brain. The technology is aimed for the treatment of major depression and chronic neuropathic pain. The company was founded in 2000 and has its headquarters in Helsinki.

Read more on company page

Key Estimate Figures05.07.2023

202223e24e
Revenue9.56.89.0
growth-%48.9 %-28.2 %31.9 %
EBIT (adj.)0.8-1.1-0.1
EBIT-% (adj.)8.8 %-16.7 %-1.1 %
EPS (adj.)0.18-0.17-0.03
Dividend0.000.000.00
Dividend %
P/E (adj.)22.8neg.neg.
EV/EBITDA22.0neg.254.5

Forum discussions

Even if you think that Brainlab is intentionally shifting deals to 2026, please note that hospital budgets are strict and annual. If money is...
1 hour ago
by Hannu
3
It’s interesting that Danes also talk about treating OCD, whereas in the table at the end of this TMS device comparison made by a Florida clinic...
4 hours ago
by ghoul
2
It has been quite clearly stated that the guaranteed sales margin will continue for future years as well. Its amount, however, will increase...
6 hours ago
by Kyhnykeisari
0
I don’t personally recall such an announcement from Karvinen, but I find this reasoning more sensible than the sudden cessation of store announcements...
17 hours ago
by Tee
5
I have speculated that the end of the year may have also focused on many NBS6 updates that do not cross the reporting threshold. This year, ...
17 hours ago
by JJ JJ
5
It’s a bit nerve-wracking what will come out of it when nothing is announced. I’d like to add more, but what if… It’s already one of the biggest...
yesterday
by QRB Strong buy
8
I just saw the same thing myself. I’ve come to the conclusion that no deals will be announced for December. Otherwise, it would be too easy ...
yesterday
by Hannu
9
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.